Our CEO Carla Landolfi took part as a speaker during the 7th summit of impurities: Genotoxic, Nitrosamine & Beyond, with a lecture titled “Setting limits for novel N-nitrosamines in Active Pharmaceutical Ingredients – State of the art of strategies and approaches for assessing acceptable intakes”.
The summit took place in Milan, Italy, organized by Vonlanthen group.
The lecture was focused on the ISO 10993 series, with a specific emphasis on biological evaluation and its relevance to Nitrosamines. It commenced by introducing the medical device regulatory framework and subsequently delved into the topic of Biological Evaluation for Genotoxicity.